Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/04/25
Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a BetZacks Investment Research • 10/31/25
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?The Motley Fool • 10/31/25
Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers TranscriptSeeking Alpha • 10/23/25
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund AdvancementBenzinga • 10/23/25
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025GlobeNewsWire • 10/06/25
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/17/25
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceGlobeNewsWire • 08/26/25
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/05/25
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/05/25
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to TradeZacks Investment Research • 07/30/25
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/29/25
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?Zacks Investment Research • 07/14/25
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung CancerGlobeNewsWire • 06/27/25
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?Zacks Investment Research • 06/23/25
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 05/27/25
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid TumorsGlobeNewsWire • 05/21/25
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/12/25
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/12/25
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 05/05/25
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025GlobeNewsWire • 05/01/25
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025GlobeNewsWire • 03/25/25